TY - JOUR T1 - In-stent Restenosis after Drug-eluting Stent Implantation in Rheumatoid Arthritis: Possible Protective Effect of Methotrexate JF - The Journal of Rheumatology JO - J Rheumatol SP - 1336 LP - 1338 DO - 10.3899/jrheum.180171 VL - 45 IS - 9 AU - OH CHAN KWON AU - JI SEON OH AU - YONG-GIL KIM Y1 - 2018/09/01 UR - http://www.jrheum.org/content/45/9/1336.abstract N2 - Patients with rheumatoid arthritis (RA) are at higher risk of cardiovascular events compared with the general population1. Therefore, these patients with RA have a greater chance of undergoing percutaneous coronary intervention (PCI). In-stent restenosis (ISR) after PCI results from damage to arteries with subsequent neointimal tissue proliferation2 and is considered the most significant problem in coronary interventional treatment. Compared with bare-metal stents (BMS), drug-eluting stents (DES) have dramatically reduced the rate of ISR3. Nevertheless, ISR after DES still exists, with an occurrence of 3–20%.Methotrexate (MTX), the most important drug used in RA, is a folate antagonist that blocks the S phase of cell division and consequently blocks mitosis4. An intravenous injection of MTX resulted in the reduction of in-stent neoatherosclerosis in an animal model5. Further, a clinical study suggested the positive effect of oral MTX on ISR after BMS implantation6. However, little is known about the effect of oral MTX on ISR after DES implantation. Therefore, we aimed to assess whether the oral administration of MTX in … Address correspondence to Dr. Y.G. Kim, Division of Rheumatology, University of Ulsan, College of Medicine, Asan Medical Center, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea. E-mail: bestmd2000{at}amc.seoul.kr ER -